A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Crossover, Single Oral Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06412562 In Healthy Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs PF 6412562 (Primary)
- Indications Cognition disorders
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
- 18 Feb 2014 New trial record